Last reviewed 2026-06-02 · How we verify

LBH589, Paclitaxel, Carboplatin, Bevacizumab

SCRI Development Innovations, LLC · Phase 1 active Small molecule ✓ Verified Jun 2026

LBH589, Paclitaxel, Carboplatin, Bevacizumab is a Small molecule drug developed by SCRI Development Innovations, LLC. It is currently in Phase 1 development.

LBH589 is a small molecule DNA inhibitor used in the treatment of various solid tumors, including anatomic stage IV breast cancer and ann Arbor stage III Hodgkin lymphoma. It is often combined with Paclitaxel and Carboplatin, with or without Bevacizumab, in clinical trials for these conditions.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LBH589, Paclitaxel, Carboplatin, Bevacizumab
Sponsor	SCRI Development Innovations, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LBH589, Paclitaxel, Carboplatin, Bevacizumab CI brief — competitive landscape report
LBH589, Paclitaxel, Carboplatin, Bevacizumab updates RSS · CI watch RSS
SCRI Development Innovations, LLC portfolio CI

Frequently asked questions about LBH589, Paclitaxel, Carboplatin, Bevacizumab

What is LBH589, Paclitaxel, Carboplatin, Bevacizumab?

LBH589, Paclitaxel, Carboplatin, Bevacizumab is a Small molecule drug developed by SCRI Development Innovations, LLC.

Who makes LBH589, Paclitaxel, Carboplatin, Bevacizumab?

LBH589, Paclitaxel, Carboplatin, Bevacizumab is developed by SCRI Development Innovations, LLC (see full SCRI Development Innovations, LLC pipeline at /company/scri-development-innovations-llc).

What development phase is LBH589, Paclitaxel, Carboplatin, Bevacizumab in?

LBH589, Paclitaxel, Carboplatin, Bevacizumab is in Phase 1.

Manufacturer: SCRI Development Innovations, LLC — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing